Pfizer has agreed to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform. The price was not disclosed. Based in La Jolla, CA, CovX will operate as a division of Pfizer’s new Biotherapeutic and Bioinnovation Center. Said Jeffrey Kindler, chairman and chief executive officer of Pfizer, “The acquisition of CovX is a further step in Pfizer’s strategy to acquire an...